What We're Reading: Page 272
Industry reads hand-picked by our editors
Jul 09, 2018
-
Forbes
Vivek Ramaswamy's Enzyvant asks FDA to approve treatment for dying babies
-
Bloomberg
Bankers quit Goldman, Citigroup for biotech riches in Hong Kong
-
San Francisco Chronicle
Berkeley boy was ‘Patient X’ in first FDA-approved medicine derived from marijuana
-
FierceBiotech
Abingworth raises $315M to place transatlantic biotech bets
Jul 06, 2018
Jul 05, 2018
-
Reuters
Drugmakers try evasion, tougher negotiations to fight new U.S. insurer tactic
-
New England Journal of Medicine
Chimeric Antigen Receptor Therapy
-
Financial Times
GSK director sued over US opioid epidemic
-
The New York Times
Alfred Alberts, Unsung Father of a Cholesterol Drug, Dies at 87
Jul 03, 2018
Jul 02, 2018
-
The New York Times
Emergency Rooms Run Out of Vital Drugs, and Patients Are Feeling It
-
Financial Times
Chinese investment into US biotech start-ups soars
-
Bloomberg
New Takeda HQ Flaunts Global Ambition Alongside Japan Roots
Jun 29, 2018
Jun 28, 2018
-
Washington Examiner
Trump administration plays regulatory hardball in drug-price talks
-
Reuters
Takeda shareholders bin proposal from anti-Shire group
-
BioCentury
Broader CFIUS jurisdiction may have implications for biotech
-
FiveThirtyEight
A Flawed Statistical Method Was Just Banned From A Major Sports Science Journal
Previous
